Archive · 31 Jul 2026
Sun Pharma Targets Q4 FY27 Completion of Organon Deal
Sun Pharma, a big Indian drug company, wants to buy a U.S. company called Organon for about $11.75 billion.
They plan to finish the deal in the last quarter of their 2027 financial year.
In the first quarter of 2027, Sun Pharma made more money and sold more drugs, especially in India.
They also sold a new drug called semaglutide in India, Brazil, and South Africa.
The company is getting approvals from regulators and the Organon shareholders to make the purchase happen.
Sun Pharma expects to close its $11.75 billion acquisition of Organon in Q4 FY27.
The company reported a 27 % rise in net profit to ₹2,894 cr and 10 % revenue growth to ₹15,183 cr in Q1 FY27.
Organon shareholders have approved the deal and Sun Pharma is obtaining regulatory approvals worldwide.
Domestic formulation sales in India grew 16 % to ₹5,474 cr, while U.S. generics sales fell 9.7 % to $427 m.
Sun Pharma’s innovative medicines, including semaglutide, drove growth in India, Brazil, and South Africa.
- Who
- Sun Pharmaceutical Industries Ltd and its management
- What
- Acquisition of US-based Organon
- When
- Expected to close in Q4 FY27
- Where
- Global markets, including India, the United States, Brazil, and South Africa
- Why
- To expand product portfolio and integrate Organon's capabilities
- Acquisition Value
- $11.75 billion
- Expected Completion
- Q4 FY27
- Q1 FY27 Net Profit
- ₹2,894 crore
- Q1 FY27 Revenue
- ₹15,183 crore
- Domestic Sales Growth
- 16% to ₹5,474 crore